Clinical trial
Dental Pain 3rd Molar Tooth Extraction GW842166
NCT00444769 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00444769 |
|---|---|
| Title | Dental Pain 3rd Molar Tooth Extraction GW842166 |
| Official title | A Multi-Centre, Randomised, Single-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy of Single Pre-Emptive Doses of GW842166X, a Non-Cannabinoid CB2 Receptor Agonist, on Pain Following Third Molar Tooth Extraction. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain |
| Intervention type | Drug |
| Interventions | GW842166 |
| Enrollment | 112 |
| Start date | Oct 1, 2006 |
| First posted | Mar 8, 2007 |
| Last update posted | May 18, 2009 |
| Countries | Germany, Italy, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: